about
Pharmacokinetic data and therapeutic efficacy of miocamycin: serum, urinary and prostatic levels. Therapeutic aspects in acute urethral syndrome and non-gonococcal urethritis.Some features of miocamycin in the gynecological field: pharmacokinetic data using preoperative administration and therapeutic aspects against chlamydial infections.Management of aerobic vaginitis.Macrolides: present and future. An appraisal of in-vitro activity and pharmacokinetic behavior.Evaluation of resistance to low pH and bile salts of human Lactobacillus spp. isolates.Key Roles of Human Polymorphonuclear Cells and Ciprofloxacin in Lactobacillus Species Infection Control.Anti-Adhesion Activity of A2-type Proanthocyanidins (a Cranberry Major Component) on Uropathogenic E. coli and P. mirabilis Strains.In vitro activity of rufloxacin against Listeria monocytogenes, Legionella pneumophila, and Chlamydia trachomatis.In-vitro and in-vivo activity of roxithromycin against Chlamydia trachomatis.Therapeutic considerations about psittacosis: remarks on a case of family psittacosis.Synthesis, characterization and in vitro evaluation of amphiphilic ion pairs of erythromycin and kanamycin antibiotics with liposaccharides.Preparation and Microbiological Evaluation of Amphiphilic Kanamycin-Lipoamino Acid Ion-PairsTwo new point mutations at A2062 associated with resistance to 16-membered macrolide antibiotics in mutant strains of Mycoplasma hominis.Antimycoplasmal activity of hydroxytyrosol.In vitro antiviral activity of Melaleuca alternifolia essential oil.Effects on adhesiveness and hydrophobicity of sub-inhibitory concentrations of netilmicin.In vitro antimycoplasmal activity of Melaleuca alternifolia essential oil.Labeling quality and molecular characterization studies of products containing Lactobacillus spp. strains.In vitro antimycoplasmal activity of oleuropein.Combining molecular modeling with experimental methodologies: mechanism of membrane permeation and accumulation of ofloxacin.Influenza virus prophylaxis.Econazole-polycarbophil, a new delivery system for topical therapy: microbiological and clinical results on vaginal candidiasis.Antimicrobial and Anti-Proliferative Effects of Skin Mucus Derived from Dasyatis pastinaca (Linnaeus, 1758).The impact of prulifloxacin on vaginal lactobacillus microflora: an in vivo study.Pefloxacine mesilate- and ofloxacin-loaded polyethylcyanoacrylate nanoparticles: characterization of the colloidal drug carrier formulation.In vitro antimycoplasmal activity of Citrus bergamia essential oil and its major components.In-vitro antimycoplasmal activity of flurithromycin.Further characterization of the in vitro and in vivo activity of ciprofloxacin against mycoplasmas.A Method for Efficient Loading of Ciprofloxacin Hydrochloride in Cationic Solid Lipid Nanoparticles: Formulation and Microbiological Evaluation.Amphiphilic ion pairs of tobramycin with lipoamino acidsLongitudinal study on the therapy of Mycoplasma pneumoniae infections with ciprofloxacin on Syrian hamstersInhibitory effects of 3-imino-5-phenyl-3H-1,2-dithiole on poliovirus type 1 replication in vitroAnti-mycoplasmal activity of a new macrolide: miocamycinSerum IgA antibodies in HSV asymptomatic genital infectionsSeroprevalence to some TORCH agents in a Sicilian female population of fertile ageGenetic basis of natural resistance to erythromycin in Mycoplasma hominisFemale genital tissue concentrations of roxithromycinTopical kanamycin: an effective therapeutic option in aerobic vaginitisSome methodological problems in the control of human mycoplasma infections
P50
Q31021117-8BE18825-9248-4BCF-A131-5E603A9D7FF4Q31021123-16142C0E-8CCF-44F8-9227-C1044C4D7B09Q33738686-16A7845D-7F4B-4EB8-8574-B940F90E8E2DQ34663891-D8115C7B-6216-4A7B-90C0-0D9827562D23Q35718022-45AE1A13-7788-4196-85F1-C0460AEA3D49Q36644701-A5073C91-7000-41E5-A9E7-2683A167BCEEQ36683711-A8EE5933-42DC-4EA1-9B23-7B59AC14456CQ37889267-04A4CC05-7053-4767-B8E2-7E7F06A30113Q37895435-5E6D4FDE-5DFF-400B-B5C6-63D7B73CA59EQ37897991-317BA196-F359-458D-AF18-1467C7B231BCQ38861241-EC9AC15A-F165-48EC-8AF7-AA4B62BB9011Q38977884-905447D6-37D6-461F-A04A-5D8E8C711B0AQ39478683-9C22115A-77B4-4B84-8E21-000FC7971749Q40425576-4D362A4F-3CB2-4934-A660-01AD80F25A55Q43258222-EECE3CED-8C1D-4178-8922-5157ACA1C741Q43433733-7827816A-2356-4BA9-827B-EE9CE0DDEE72Q43439100-941CBF9D-0177-4F22-BE4B-DF5CF820AA32Q43618622-97187500-2383-4FC0-B0EE-247DA4389B10Q44183669-DCF30B50-2996-4BA6-AED2-5575C183AD16Q44203203-A70DA8A2-E496-43BE-8DC1-42C215CA5459Q45422152-2076E836-34D5-417D-9BE0-F7FB2C36EDBBQ46497520-2C366EE4-BA9B-496F-8E42-7648F19335D8Q47103329-037B8D6A-A858-4F86-848E-6E34C6156146Q51592063-9C1379C7-D1FB-45D3-BFB3-9B2AD2142237Q52337768-C5E32885-D4AD-4656-BD28-3BC6BC57A2D8Q52735915-9E78B0E3-B6A9-4FFE-AB9E-10A5DF49C454Q54186251-5A899E14-28A2-4E97-999B-93A18ED70F9BQ54399771-B8797BD6-8FCD-4C33-A194-D7E83AC685DDQ55262718-3D8311ED-6B7C-4515-A87C-6EA2E18DE897Q59227816-00F3BA1F-104F-447C-9287-D989B0D6531CQ67256343-64485D20-9E83-48DB-9A2F-51814BE67359Q68078690-192E0233-8162-43CB-8893-6ED7326A1F6AQ68835725-01BE54DD-0786-4D0B-99BD-F483C48C3DBAQ69349331-D484F2E7-7379-4A59-83C1-90D0795031F5Q70494221-7042F90F-8EFA-4CC8-B345-6E14B1A01A0BQ73626128-6E0BB052-6312-46B6-9BD9-245D60BD0A75Q74218169-136350EB-3B4D-4415-805D-7860843F60C8Q79197984-04BDBC69-9CF4-449A-9BCF-C7E76C94198FQ81541273-FCA701AE-BC89-4A5C-A360-29B8EE2B27CA
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Pio Maria Furneri
@ast
Pio Maria Furneri
@en
Pio Maria Furneri
@es
Pio Maria Furneri
@nl
Pio Maria Furneri
@sl
type
label
Pio Maria Furneri
@ast
Pio Maria Furneri
@en
Pio Maria Furneri
@es
Pio Maria Furneri
@nl
Pio Maria Furneri
@sl
prefLabel
Pio Maria Furneri
@ast
Pio Maria Furneri
@en
Pio Maria Furneri
@es
Pio Maria Furneri
@nl
Pio Maria Furneri
@sl
P1053
L-4655-2013
P106
P1153
7004523816
P21
P2798
P31
P3829
P496
0000-0003-1782-9758
P569
2000-01-01T00:00:00Z